<DOC>
	<DOCNO>NCT02115139</DOCNO>
	<brief_summary>Ipilimumab add clinical benefit radiation therapy patient melanoma metastatic brain . Melanoma third common cancer cause brain metastasis , cancer lung breast , appear reflect relative propensity melanoma metastasize central nervous system ( CNS ) . Brain metastases responsible 20 54 percent death patient melanoma , among documented brain metastasis , lesion contribute death 95 percent case , estimate median overall survival range 1.8 10.5 month , depend upon prognostic factor . Ipilimumab anti-Cytotoxic T-Lymphocyte Antigen 4 ( anti-CTLA4 ) monoclonal antibody demonstrate clinically relevant statistically significant improvement overall survival , either alone ( second line ) combination dacarbazine ( DTIC ) 1st line . Ipilimumab show activity brain metastasis . According European Medicines Agency ( EMA ) approve label Yervoy® , use glucocorticoid baseline ( commonly prescribe brain metastasis diagnose ) avoid administration ipilimumab . Data show use even high dos glucocorticoids management immune-related adverse event decrease efficacy Yervoy® . There documented experience efficacy Yervoy® give concomitantly radiation therapy glucocorticoid . In experimental model , radiation therapy synergistic anti-Cytotoxic T-Lymphocyte Antigen 4 ( anti-CTLA4 ) strategy ( abscopal effect ) . There publish result clinical trial interaction radiation therapy ipilimumab .</brief_summary>
	<brief_title>GEM STUDY : Radiation And Yervoy Patients With Melanoma Brain Metastases</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Willing able give write informed consent . 2 . Histologic diagnosis melanoma . 3 . First episode radiological evidence brain metastasis 4 . Be age 18 year old 5 . Radiation Therapy Oncology Grouprecursive partition analysis ( RTOGRPA ) class 2 6 . Karnofsky performance status ( PS ) 70 % 7 . Barthel Index Activities Daily Living 10 8 . Measurable disease ( mWHO criterion ) . 9 . Adequate organ function determine follow criterion : White blood count ( WBC ) equal 2000/ microliter ( uL ) Absolute neutrophil count ( ANC ) 1.5 x 109/L . Platelet count 75 x 109/L . Hemoglobin 9 g/dL . If patient receive red blood count ( RBC ) transfusion , require value hemoglobin meet least 1 week recent transfusion . Serum creatinine less equal 2.0 x upper limit normal ( ULN ) . Serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) less equal 2.5 x ULN patient without liver metastasis , less equal 5 time liver metastasis . Total bilirubin less equal 2.0 x ULN , ( except patient Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) 10 . Persons reproductive potential must agree use adequate method contraception throughout treatment least 26 week ipilimumab stop 1 . Patients melanoma brain metastasis follow diseasespecific characteristic : Documented evidence prior progression melanoma ipilimumabcontaining regimen ( i.e . receive least 2 dos ipilimumab either advanced disease adjuvant set disease progressed/relapsed ( accord mWHO criterion ) within 24 week since first dose ipilimumab ) Prior radiation therapy brain Other prior antineoplastic therapy brain metastasis . Patients cerebral metastasis location disease , local therapy ( neurosurgery , radiosurgery ) could achieve diseasefree status Patients rapid clinical deterioration , risk herniation , require unstable ascend dose supportive medication last week include anticonvulsivants , steroid analgesic , require dexamethasone 16 mg/d ( glucocorticoid equipotent dose ) , high lactate dehydrogenase ( LDH ) 2 x ULN . 2 . Any malignancy form patient diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer carcinoma situ cervix , incidental prostate cancer . 3 . Uncontrolled diabetes mellitus ( HbA1c 9 % ) 4 . Autoimmune disease vitiligo past thyroiditis substitutive hormone therapy : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome Myasthenia Gravis ) . 5 . Other chronic intestinal disease associate diarrhea . 6 . Active infection serious illness medical condition . 7 . Known active chronic infection HIV , Hepatitis B , Hepatitis C. 8 . Concomitant therapy following : interleukin2 ( IL2 ) , interferon , nonstudy immunotherapy regimen ; cytotoxic chemotherapy ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid ( used management noncancer related illness ) , either concomitantly last 30 day prior begin treatment . 9 . Any experimental therapy administer past 30 day prior begin treatment . 10 . Any nononcology vaccine therapy use prevention infectious disease ( 4 week prior dose blind study drug ) ( see definition protocol text ) 11 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( eg , infectious ) illness . 12 . Any general , medical psychological condition opinion investigator make administration ipilimumab hazardous , would preclude appropriate inform consent compliance protocol , obscure interpretation eventual adverse event ( AEs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>melanoma</keyword>
	<keyword>brain</keyword>
	<keyword>metastasis</keyword>
	<keyword>Patients melanoma brain metastasis</keyword>
</DOC>